Tandem Diabetes Care (TNDM) Convertible Debt (2020 - 2026)

Tandem Diabetes Care has reported Convertible Debt for 7 years, with the latest figure at $601.8 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt rose 94.93% year-over-year to $601.8 million; the trailing twelve-month figure through Mar 2026 stood at $601.8 million (up 94.93% YoY), and the FY2025 full-year result was $310.0 million, up 0.57% from the prior year.
• Convertible Debt for Q1 2026 stood at $601.8 million, up from $310.0 million in the prior quarter.
• The five-year high for Convertible Debt was $601.8 million in Q1 2026, with the low at $281.9 million in Q1 2022.
• Historically, Convertible Debt has averaged $316.3 million across 5 years, with a median of $307.4 million in 2024.
• Annual changes were most pronounced in 2025 — Convertible Debt retreated 11.16% — and 2026, when it surged 94.93%.
• Tandem Diabetes Care's Convertible Debt stood at $283.2 million in 2022, then increased by 0.64% to $285.0 million in 2023, then rose by 8.15% to $308.3 million in 2024, then climbed by 0.57% to $310.0 million in 2025, then soared by 94.1% to $601.8 million in 2026.
• The last three Convertible Debt figures came in at $601.8 million (Q1 2026), $310.0 million (Q4 2025), and $309.6 million (Q3 2025), per Business Quant data.